EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

Andrew J Armstrong iD, Arun A Azad iD, Taro Iguchi iD, Arnulf Stenzl iD, Nicolas Mottet, David Russell, Matt Rosales, Gabriel P Haas, Fred Saad iD, Maha Hussain iD, Cora N Sternberg iD

Journal of Clinical Oncology · 10.05.2026 · 44 (14) · 1309-1322

DOI: 10.1200/jco-24-02829 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.05.2026. Verfasst von Andrew J Armstrong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC. Hauptthemen laut MEDLINE: Nitriles, Benzamides, Prostate-Specific Antigen, Phenylthiohydantoin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE In patients who received enzalutamide, we characterized the development of radiographic progression (rPD) without prostate-specific antigen (PSA) rise or progression in metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC). Methods We conducted a post hoc analysis in two phase III trials (N = 2,551; ARCHES [ClinicalTrials.gov identifier: NCT02677896 ]; PROSPER [ClinicalTrials.gov identifier: NCT02003924 ]) for co-occurrence of rPD ± Prostate Cancer Working Group 2/3-defined PSA progression, and rPD ± any PSA rise from baseline/nadir by treatment. Kaplan-Meier methods were used for overall survival (OS) outcomes. RESULTS In ARCHES, 3.5% and 8.5% of 574 patients with mHSPC treated with enzalutamide plus androgen-deprivation therapy (ADT) had no PSA rise or PSA progression at rPD, respectively. Of 79 patients with rPD who received enzalutamide plus ADT, 25.3% had no PSA rise and 62.0% did not meet PSA progression criteria compared with 7.4% and 38.3% of 188 patients with rPD treated with ADT alone, respectively. In PROSPER, 4.4% and 10.3% of 933 patients with nmCRPC treated with enzalutamide plus ADT had no PSA rise or PSA progression, respectively, at rPD. However, of 187 patients with rPD who received enzalutamide plus ADT, 21.9% had no PSA rise and 51.3% did not meet PSA progression criteria compared with 3.6% and 18.8% of 224 patients treated with placebo/ADT, respectively. Liver metastases were >5-fold higher in enzalutamide-treated patients with rPD events versus control, although sample size was small. Compared with no rPD, enzalutamide-treated patients with rPD ± PSA rise or progression had worse OS. CONCLUSION Given the frequent discordance and poor prognosis of imaging-based progression in the absence of PSA changes during enzalutamide treatment in mHSPC and nmCRPC, periodic surveillance using imaging is recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitrilesBenzamidesProstate-Specific AntigenPhenylthiohydantoinProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantHumansMaleDisease ProgressionAgedMiddle AgedAndrogen Antagonists

Substanzen

enzalutamideNitrilesBenzamidesProstate-Specific AntigenPhenylthiohydantoinAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Medicine, Division of Medical Oncology, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC.
  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
  • Department of Urology, Kanazawa Medical University, Ishikawa, Japan.
  • Department of Urology, University of Tübingen, Tübingen, Germany.
  • Department of Urology, University Hospital, St Etienne, France.

ORCID-Profile: Andrew J Armstrong, Arun A Azad, Taro Iguchi, Arnulf Stenzl, Fred Saad, Maha Hussain, Cora N Sternberg

Zitieren

APA

Armstrong, A. J., Azad, A. A., Iguchi, T., Stenzl, A., Mottet, N., Russell, D., Rosales, M., Haas, G. P., Saad, F., Hussain, M., & Sternberg, C. N. (2026). Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. Journal of Clinical Oncology, 44(14), 1309-1322. https://doi.org/10.1200/jco-24-02829

Vancouver

Armstrong AJ, Azad AA, Iguchi T, Stenzl A, Mottet N, Russell D, et al. Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. Journal of Clinical Oncology. 2026;44(14):1309-1322. doi:10.1200/jco-24-02829

BibTeX
@article{Armstrong2026,
  author = {Armstrong, Andrew J and Azad, Arun A and Iguchi, Taro and Stenzl, Arnulf and Mottet, Nicolas and Russell, David and Rosales, Matt and Haas, Gabriel P and Saad, Fred and Hussain, Maha and Sternberg, Cora N},
  title = {Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {14},
  pages = {1309--1322},
  doi = {10.1200/jco-24-02829}
}
Kostenlos starten →